Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BMRN

Biomarin Pharmaceutical Inc

Mar 19 • 09:45AM ET

71.82

Dollar change +0.30
Percentage change 0.41	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX SRPT NBIX ALNY BLUE IONS RARE EXEL PRTA

| Held by: IJH VTI VXF VB XBI VO MDY VBK VUG IBB

Scroll to Statements

Index	-	P/E	32.65	EPS (ttm)	2.20	Insider Own	1.27%	Shs Outstand	190.76M	Perf Week	1.81%
Market Cap	13.70B	Forward P/E	17.40	EPS next Y	4.13	Insider Trans	-0.56%	Shs Float	188.35M	Perf Month	10.72%
Income	426.86M	PEG	1.05	EPS next Q	0.70	Inst Own	97.79%	Short Float	2.25%	Perf Quarter	8.79%
Sales	2.84B	P/S	4.83	EPS this Y	43.44%	Inst Trans	1.52%	Short Ratio	2.80	Perf Half Y	2.80%
Book/sh	29.66	P/B	2.42	EPS next Y	30.19%	ROA	6.17%	Short Interest	4.24M	Perf Year	-14.37%
Cash/sh	5.96	P/C	12.04	EPS next 5Y	31.14%	ROE	8.05%	52W Range	60.63 - 94.85	Perf YTD	9.26%
Dividend Est.	-	P/FCF	28.11	EPS past 5Y	-	ROI	6.79%	52W High	-24.29%	Beta	0.30
Dividend TTM	-	Quick Ratio	3.29	Sales past 5Y	11.18%	Gross Margin	78.04%	52W Low	18.45%	ATR (14)	1.77
Dividend Ex-Date	-	Current Ratio	5.33	EPS Y/Y TTM	151.40%	Oper. Margin	16.74%	RSI (14)	62.10	Volatility	2.49% 2.77%
Employees	3040	Debt/Eq	0.11	Sales Y/Y TTM	17.35%	Profit Margin	15.03%	Recom	1.52	Target Price	97.73
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	507.25%	Payout	0.00%	Rel Volume	0.27	Prev Close	71.52
Sales Surprise	4.87%	EPS Surprise	19.85%	Sales Q/Q	14.29%	Earnings	Feb 19 AMC	Avg Volume	1.51M	Price	71.82
SMA20	1.84%	SMA50	7.80%	SMA200	-2.63%	Trades		Volume	35,060	Change	0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-24-25	Upgrade	Oppenheimer	Perform → Outperform	$98
Nov-15-24	Initiated	Wolfe Research	Outperform	$95
Oct-30-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-10-24	Resumed	Raymond James	Outperform	$79
Aug-20-24	Upgrade	Bernstein	Mkt Perform → Outperform	$94 → $110
May-17-24	Downgrade	Robert W. Baird	Outperform → Neutral	$104 → $72
May-14-24	Initiated	Evercore ISI	Outperform	$113
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116
Jan-30-23	Initiated	BMO Capital Markets	Market Perform	$107
Jan-18-23	Initiated	Canaccord Genuity	Hold	$119
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform	$92 → $110

Show Previous Ratings

Today 05:05AM	A Look Back at Therapeutics Stocks Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack (StockStory)
Mar-18-25 05:55AM	Is BioMarin Pharmaceutical (BMRN) the Best Biotech Stock According to Billionaires? (Insider Monkey)
Mar-17-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Mar-12-25 12:45PM	Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
09:55AM	Wall Street Analysts Believe BioMarin (BMRN) Could Rally 36.57%: Here's is How to Trade (Zacks)
09:50AM	Loading…
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Mar-11-25 09:01AM	1 Healthcare Stock to Target This Week and 2 to Turn Down (StockStory)
05:03AM	Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks (StockStory)
Mar-05-25 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-28-25 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Feb-25-25 09:00AM	BioMarin to Present at the TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 6:50 AM PT / 9:50 AM ET in Boston, MA (PR Newswire)
08:03AM	Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
08:03AM	What To Expect From United Therapeuticss (UTHR) Q4 Earnings (StockStory)
Feb-24-25 04:05PM	BioMarin Announces Appointment of Timothy P. Walbert to Board of Directors (PR Newswire)
12:45PM	Loading…
12:45PM	BioMarin (BMRN) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
10:24AM	Oppenheimer upgrades BioMarin on long term outlook (Investing.com)
09:55AM	Does BioMarin (BMRN) Have the Potential to Rally 40.54% as Wall Street Analysts Expect? (Zacks)
09:37AM	Alibaba upgraded, Rivian downgraded: Wall Street's top analyst calls (The Fly)
Feb-21-25 09:25AM	BioMarin price target raised to $80 from $78 at Scotiabank (TipRanks)
06:00AM	Pfizer stops selling hemophilia gene therapy, citing weak demand (BioPharma Dive)
Feb-20-25 05:56PM	Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today (Motley Fool)
02:42PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
01:50PM	Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today (StockStory)
09:39AM	Why Is BioMarin Stock Trading Higher On Thursday? (Benzinga)
07:30AM	Q4 2024 BioMarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
02:11AM	Biomarin Pharmaceutical Inc (BMRN) Q4 2024 Earnings Call Highlights: Record Growth and ... (GuruFocus.com)
Feb-19-25 05:30PM	Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics (Zacks)
05:20PM	BioMarin Pharmaceutical (BMRN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:32PM	BioMarin: Q4 Earnings Snapshot (Associated Press Finance)
04:21PM	Loading…
04:21PM	BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars (StockStory)
04:05PM	BioMarin Reports Fourth Quarter and Full Year 2024 Results; Sets Full Year 2025 Guidance (PR Newswire)
Feb-18-25 08:06AM	What To Expect From BioMarin Pharmaceuticals (BMRN) Q4 Earnings (StockStory)
Feb-13-25 09:15AM	Unveiling BioMarin (BMRN) Q4 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Feb-12-25 10:00AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Feb-08-25 08:58AM	Why BioMarin Pharmaceutical Inc. (BMRN) Is Among the Best Healthcare Stocks To Buy According to Analysts (Insider Monkey)
Feb-05-25 12:45PM	3 Reasons Growth Investors Will Love BioMarin (BMRN) (Zacks)
09:00AM	BioMarin to Host Fourth Quarter and Full-Year 2024 Financial Results Conference Call and Webcast on Wednesday, February 19, 2025, at 4:30pm ET (PR Newswire)
Feb-04-25 10:01AM	Tasso and Arup to develop blood testing services for clinical research (Medical Device Network)
Jan-27-25 03:04PM	Is BioMarin Pharmaceutical (BMRN) the Best Depressed Stock to Invest in Now? (Insider Monkey)
09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Jan-23-25 06:45AM	Why Is Andreas Halvorsen Bullish On BioMarin Pharmaceutical Inc. (BMRN) Now? (Insider Monkey)
Jan-20-25 09:57PM	BioMarin Pharmaceutical Inc. (BMRN) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 (Insider Monkey)
12:45PM	Here is Why Growth Investors Should Buy BioMarin (BMRN) Now (Zacks)
Jan-13-25 12:00PM	BioMarin Announces Legal Action Against Ascendis Pharma A/S in European Unified Patent Court (PR Newswire)
09:55AM	Wall Street Analysts Predict a 45.86% Upside in BioMarin (BMRN): Here's What You Should Know (Zacks)
09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Jan-09-25 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Jan-06-25 08:30AM	BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 am PT / 12:00 pm ET, in San Francisco, CA (PR Newswire)
Jan-03-25 05:06AM	10 Magnificent Stocks That Can Make You Richer in 2025 (Motley Fool)
Jan-02-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) (Zacks)
Dec-26-24 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Dec-24-24 09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Dec-19-24 08:38AM	Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock? (Zacks)
Dec-11-24 09:50AM	BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Dec-09-24 03:31PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Nov-28-24 11:31AM	Why Is BioMarin (BMRN) Down 1.9% Since Last Earnings Report? (Zacks)
Nov-27-24 09:20AM	Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Healthcare Stocks in 2024? (Insider Monkey)
Nov-21-24 05:26PM	Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Biotech Stocks in 2024? (Insider Monkey)
09:40AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock (Zacks)
Nov-20-24 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Nov-19-24 06:54PM	BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now (Insider Monkey)
Nov-16-24 10:45AM	BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 (PR Newswire)
Nov-12-24 08:30AM	Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options (Zacks)
Nov-07-24 09:35AM	Heres Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) (Insider Monkey)
Nov-06-24 08:00AM	BioMarin to Participate in Three Upcoming Investor Conferences (PR Newswire)
Nov-05-24 09:40AM	Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term (Zacks)
Nov-04-24 12:45PM	Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
12:00PM	BioMarin (BMRN) Upgraded to Buy: Here's Why (Zacks)
09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Nov-01-24 01:12AM	Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN) (GuruFocus.com)
Oct-31-24 07:33AM	BioMarin price target raised to $106 from $104 at UBS (TipRanks)
Oct-30-24 12:14PM	Q3 2024 BioMarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
10:19AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
03:13AM	Biomarin Pharmaceutical Inc (BMRN) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Oct-29-24 06:30PM	BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:20PM	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates (Zacks)
04:20PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:03PM	BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook (PR Newswire)
Oct-24-24 07:00AM	Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate (GlobeNewswire)
06:32AM	BioMarin Pharmaceutical (BMRN): Hedge Funds Back Biotech Leader Amid Record Revenue Growth (Insider Monkey)
Oct-22-24 10:01AM	BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-17-24 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Oct-16-24 08:30AM	BioMarin to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Tuesday, October 29, 2024, at 4:30pm ET (PR Newswire)
Oct-04-24 10:04AM	Do Options Traders Know Something About BioMarin (BMRN) Stock We Don't? (Zacks)
Oct-01-24 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN) (Zacks)
09:35AM	Down -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN) (Zacks)
Sep-30-24 07:03PM	Andreas Halvorsen's Strategic Acquisition in BioMarin Pharmaceutical Inc (GuruFocus.com)
07:03PM	Andreas Halvorsen's Firm Expands Grip in BioMarin Pharmaceutical Inc Holding (GuruFocus.com)
09:45AM	Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term (Zacks)
Sep-25-24 03:50PM	BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish (Benzinga)
Sep-21-24 09:55AM	BioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem (Insider Monkey)
Sep-18-24 08:00AM	BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting (PR Newswire)
Sep-17-24 11:15AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
07:18AM	Ascendis trial data piles pressure on BioMarin (BioPharma Dive)
Sep-16-24 06:45PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research) -17.71%
04:01PM	Ascendis Rockets And Hammers BioMarin On New Results For Growth Drug (Investor's Business Daily)
03:12PM	Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term (Benzinga)
Sep-13-24 09:45AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock (Zacks)
Sep-08-24 02:03AM	BioMarin Pharmaceutical Inc. (BMRN): Is This Biotech Stock A Good Buy? (Insider Monkey)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burkhart Erin	Officer	Mar 19 '25	Proposed Sale	71.52	1,295	92,618		Mar 19 09:36 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 06 '25	Sale	71.28	7,034	501,355	87,655	Mar 07 04:06 PM
Guyer Charles Greg	Officer	Mar 06 '25	Proposed Sale	71.28	7,034	501,359		Mar 06 04:05 PM
Burkhart Erin	GVP, Chief Accounting Officer	Feb 24 '25	Sale	68.38	1,344	91,903	13,105	Feb 25 08:21 PM
Burkhart Erin	Officer	Feb 24 '25	Proposed Sale	68.38	1,344	91,903		Feb 24 10:26 AM
Guyer Charles Greg	EVP, Chief Technical Officer	Nov 12 '24	Sale	66.37	5,278	350,324	68,909	Nov 14 02:44 PM
Guyer Charles Greg	Officer	Nov 12 '24	Proposed Sale	66.37	5,278	350,324		Nov 12 02:27 PM
Burkhart Erin	GVP, Chief Accounting Officer	Aug 13 '24	Sale	90.00	714	64,260	14,449	Aug 15 03:57 PM
Burkhart Erin	Officer	Aug 13 '24	Proposed Sale	90.00	714	64,260		Aug 13 11:48 AM
HERON ELAINE J	Director	Jun 03 '24	Option Exercise	63.10	5,047	318,466	101,888	Jun 04 07:29 PM
MEIER RICHARD A	Director	Jun 03 '24	Option Exercise	63.10	6,600	416,460	126,227	Jun 04 07:28 PM
Mueller Brian	EVP, Chief Financial Officer	May 30 '24	Option Exercise	63.10	5,000	315,500	77,159	May 31 06:28 PM
Mueller Brian	EVP, Chief Financial Officer	May 30 '24	Sale	75.19	5,000	375,950	72,159	May 31 06:28 PM
Davis George Eric	EVP, Chief Legal Officer	May 28 '24	Option Exercise	63.10	40,850	2,577,635	97,007	May 30 06:18 PM
Davis George Eric	EVP, Chief Legal Officer	May 28 '24	Sale	74.51	40,850	3,043,802	56,157	May 30 06:18 PM
BIENAIME JEAN JACQUES	Director	May 09 '24	Option Exercise	63.10	20,000	1,262,000	494,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 10 '24	Option Exercise	63.10	20,000	1,262,000	494,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 09 '24	Sale	81.62	20,000	1,632,400	474,994	May 13 03:57 PM
BIENAIME JEAN JACQUES	Director	May 10 '24	Sale	81.14	20,000	1,622,800	474,994	May 13 03:57 PM
Davis George Eric	EVP, Chief Legal Officer	May 02 '24	Option Exercise	63.10	1,850	116,735	58,007	May 06 04:45 PM
Davis George Eric	EVP, Chief Legal Officer	May 02 '24	Sale	85.01	1,850	157,268	56,157	May 06 04:45 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	May 02 '24	Sale	82.91	5,000	414,550	66,767	May 06 04:40 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Option Exercise	63.10	20,000	1,262,000	494,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 12 '24	Sale	91.26	20,000	1,825,200	474,994	Apr 15 04:21 PM
BIENAIME JEAN JACQUES	Director	Apr 11 '24	Sale	90.99	20,000	1,819,800	474,994	Apr 15 04:21 PM
Burkhart Erin	GVP, Chief Accounting Officer	Apr 10 '24	Sale	90.00	2,286	205,740	16,156	Apr 12 03:07 PM
Davis George Eric	EVP, Chief Legal Officer	Mar 28 '24	Sale	88.34	24,602	2,173,341	55,856	Apr 01 04:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMRN

Biomarin Pharmaceutical Inc

Upgrade your FINVIZ experience